| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1074/JBC.270.41.23883 |
| P953 | full work available at URL | https://doi.org/10.1074/jbc.270.41.23883 |
| https://api.elsevier.com/content/article/PII:S0021925818574603?httpAccept=text/xml | ||
| https://api.elsevier.com/content/article/PII:S0021925818574603?httpAccept=text/plain | ||
| https://syndication.highwire.org/content/doi/10.1074/jbc.270.41.23883 | ||
| P698 | PubMed publication ID | 7592573 |
| P5875 | ResearchGate publication ID | 15605713 |
| P2093 | author name string | M. A. Martin | |
| E. O. Freed | |||
| P2860 | cites work | Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160 | Q22251286 |
| Human immunodeficiency virus type 1 glycoprotein precursor retains a CD4-p56lck complex in the endoplasmic reticulum | Q24630789 | ||
| Bulletin de l'Institut Pasteur | Q27714199 | ||
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition | Q28317348 | ||
| Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity | Q28646740 | ||
| Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41 | Q28646771 | ||
| Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor | Q28646793 | ||
| Identification of the fusion peptide of primate immunodeficiency viruses | Q28646799 | ||
| Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1 | Q28646812 | ||
| Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. | Q48378749 | ||
| Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. | Q50335725 | ||
| Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. | Q53534022 | ||
| A chink in HIV's armour? | Q59070021 | ||
| A soluble CD4 protein selectively inhibits HIV replication and syncytium formation | Q59081036 | ||
| Membrane fusion | Q67584890 | ||
| Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen | Q68833722 | ||
| Alterations in T4 (CD4) protein and mRNA synthesis in cells infected with HIV | Q70310627 | ||
| The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s) | Q70573568 | ||
| Relation of phenotype evolution of HIV-1 to envelope V2 configuration | Q70739957 | ||
| CD26 is not involved in infection of peripheral blood mononuclear cells by HIV-1 | Q72625455 | ||
| CD26 antigen and HIV fusion? | Q72676868 | ||
| CD26 antigen and HIV fusion? | Q93870177 | ||
| Retained in vitro infectivity and cytopathogenicity of HIV-1 despite truncation of the C-terminal tail of the env gene product | Q44898633 | ||
| Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects | Q44982560 | ||
| Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing | Q45252128 | ||
| Rous sarcoma virus p19 and gp35 can be chemically crosslinked to high molecular weight complexes. An insight into virus assembly | Q45796669 | ||
| Genetic variability of the AIDS virus: nucleotide sequence analysis of two isolates from African patients | Q45848343 | ||
| T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV | Q28646817 | ||
| The structure and function of the hemagglutinin membrane glycoprotein of influenza virus | Q29618354 | ||
| The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain | Q29618472 | ||
| Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. | Q30355613 | ||
| Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides | Q33560772 | ||
| Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 | Q33571605 | ||
| Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees | Q33582665 | ||
| Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. | Q33685950 | ||
| High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates | Q33760671 | ||
| Identification and characterization of fusion and processing domains of the human immunodeficiency virus type 2 envelope glycoprotein | Q33935988 | ||
| Viral and cellular membrane fusion proteins | Q34208540 | ||
| Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein | Q34301897 | ||
| HIV infection is blocked in vitro by recombinant soluble CD4. | Q34681034 | ||
| A soluble form of CD4 (T4) protein inhibits AIDS virus infection | Q34686801 | ||
| Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus | Q35616284 | ||
| Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteins | Q35832208 | ||
| Effects of second-site mutations on dominant interference by a human immunodeficiency virus type 1 envelope glycoprotein mutant | Q35833507 | ||
| Virion incorporation of envelope glycoproteins with long but not short cytoplasmic tails is blocked by specific, single amino acid substitutions in the human immunodeficiency virus type 1 matrix. | Q35835956 | ||
| Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding | Q36230268 | ||
| A VIRUS IN CHICK EMBRYOS WHICH INDUCES RESISTANCE IN VITRO TO INFECTION WITH ROUS SARCOMA VIRUS. | Q36437787 | ||
| Three-dimensional structure of a membrane-containing virus | Q36572306 | ||
| Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. | Q36627098 | ||
| Evidence for a functional interaction between the V1/V2 and C4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp120. | Q36632356 | ||
| Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26. | Q36636241 | ||
| Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells | Q36646920 | ||
| Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. | Q36647416 | ||
| Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. | Q36649240 | ||
| Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop | Q36651187 | ||
| Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. | Q36652422 | ||
| Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding | Q36655317 | ||
| Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates | Q36656036 | ||
| Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity | Q36656386 | ||
| Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein | Q36684443 | ||
| Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range | Q36687863 | ||
| Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2. | Q36699125 | ||
| A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity | Q36756570 | ||
| Human immunodeficiency virus envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells | Q36805743 | ||
| Human immunodeficiency virus pseudotypes with expanded cellular and species tropism | Q36806036 | ||
| The cytoplasmic domain of simian immunodeficiency virus transmembrane protein modulates infectivity | Q36831184 | ||
| Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120 | Q36833874 | ||
| Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope | Q36869394 | ||
| Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines | Q36872227 | ||
| Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1 | Q36872993 | ||
| The role of envelope glycoprotein processing in murine leukemia virus infection | Q36918689 | ||
| Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. | Q37429018 | ||
| Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes | Q37476959 | ||
| Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. | Q37577723 | ||
| Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor | Q37588188 | ||
| Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like regio | Q37594056 | ||
| Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein | Q37675018 | ||
| Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection | Q37925515 | ||
| Role of HIV-1 envelope V3 loop cleavage in cell tropism | Q39034867 | ||
| Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. | Q39090316 | ||
| HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain | Q39313963 | ||
| Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population | Q39439717 | ||
| A furin-defective cell line is able to process correctly the gp160 of human immunodeficiency virus type 1. | Q40041192 | ||
| Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120. | Q40045783 | ||
| Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region | Q40061779 | ||
| Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. | Q40109264 | ||
| Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo | Q40308974 | ||
| Paramyxovirus fusion: a hypothesis for changes | Q40767649 | ||
| Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120 | Q41078744 | ||
| Low-pH induced conformational changes in viral fusion proteins: implications for the fusion mechanism | Q41362595 | ||
| Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein | Q41448616 | ||
| T cell activation antigen, CD26, as a cofactor for entry of HIV in CD4+ cells | Q41508169 | ||
| Cell fusion activity of the simian immunodeficiency virus envelope protein is modulated by the intracytoplasmic domain | Q41517820 | ||
| Topogenic analysis of the human immunodeficiency virus type 1 envelope glycoprotein, gp160, in microsomal membranes | Q41562736 | ||
| Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene | Q41699910 | ||
| The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? | Q41701302 | ||
| Human genes other than CD4 facilitate HIV-1 infection of murine cells | Q41702917 | ||
| Dissociation of gp120 from HIV-1 virions induced by soluble CD4. | Q41714439 | ||
| Enhancement of SIV infection with soluble receptor molecules | Q41740893 | ||
| Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses | Q41743762 | ||
| Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus | Q41876028 | ||
| Identification of Conserved Residues in the Human Immunodeficiency Virus Type 1 Principal Neutralizing Determinant That Are Involved in Fusion | Q41979990 | ||
| Soluble CD4 molecules neutralize human immunodeficiency virus type 1. | Q43546755 | ||
| CD26 antigen and HIV fusion? | Q43604799 | ||
| A syncytia assay for human immunodeficiency virus type I (HIV-I) envelope protein and its use in studying HIV-I mutations | Q43654258 | ||
| Role of the HTLV-III/LAV envelope in syncytium formation and cytopathicity | Q43894349 | ||
| Studies with crosslinking reagents on the oligomeric structure of the env glycoprotein of HIV. | Q44021595 | ||
| Site-directed mutations in sindbis virus E2 glycoprotein's cytoplasmic domain and the 6K protein lead to similar defects in virus assembly and budding | Q44142968 | ||
| Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for persistence in AIDS. | Q44230518 | ||
| P433 | issue | 41 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 23883-23886 | |
| P577 | publication date | 1995-10-01 | |
| 1995-10-13 | |||
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection | |
| The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection | |||
| P478 | volume | 270 |
| Q27480846 | A 45,000-M(r) glycoprotein in the Sendai virus envelope triggers virus-cell fusion |
| Q47981910 | A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor |
| Q39597147 | A novel enzyme-linked immunosorbent assay for screening HIV-1 fusion inhibitors targeting HIV-1 Gp41 core structure |
| Q33266091 | A stiffness switch in human immunodeficiency virus |
| Q39411795 | A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency. |
| Q36827883 | A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization |
| Q43506030 | A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry |
| Q36508756 | Analysis of small molecule ligands targeting the HIV-1 matrix protein-RNA binding site |
| Q34050712 | Assessment of HIV vaccine development: past, present, and future |
| Q27746904 | Atomic structure of a thermostable subdomain of HIV-1 gp41 |
| Q34020570 | Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations |
| Q33843723 | Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis |
| Q27678797 | Biophysical characterization and crystal structure of the Feline Immunodeficiency Virus p15 matrix protein |
| Q34838416 | CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue |
| Q44898164 | Calmodulin binding properties of peptide analogues and fragments of the calmodulin-binding domain of simian immunodeficiency virus transmembrane glycoprotein 41. |
| Q33805110 | Cell-dependent requirement of human immunodeficiency virus type 1 gp41 cytoplasmic tail for Env incorporation into virions |
| Q31510236 | Characterization of the biosynthesis of human immunodeficiency virus type 1 Env from infected T-cells and the effects of glucose trimming of Env on virion infectivity. |
| Q33785977 | Cleavage of the murine leukemia virus transmembrane env protein by human immunodeficiency virus type 1 protease: transdominant inhibition by matrix mutations. |
| Q30701330 | Comparison of predicted scaffold-compatible sequence variation in the triple-hairpin structure of human imunodeficiency virus type 1 gp41 with patient data |
| Q36371928 | Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells |
| Q61814298 | Concomitant Enhancement of HIV-1 Replication Potential and Neutralization-Resistance in Concert With Three Adaptive Mutations in Env V1/C2/C4 Domains |
| Q27637906 | Conformational mapping of the N-terminal peptide of HIV-1 gp41 in membrane environments using (13)C-enhanced Fourier transform infrared spectroscopy |
| Q92727230 | Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting |
| Q44635089 | Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. |
| Q39602915 | Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. |
| Q27736064 | Core structure of gp41 from the HIV envelope glycoprotein |
| Q38356421 | Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion. |
| Q39177719 | Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry |
| Q38325401 | Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside |
| Q35020604 | Cytolysis by CCR5-using human immunodeficiency virus type 1 envelope glycoproteins is dependent on membrane fusion and can be inhibited by high levels of CD4 expression |
| Q27654848 | Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity |
| Q40797427 | Design and properties of N(CCG)-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity |
| Q40758720 | Design and synthesis of small molecule-sulfotyrosine mimetics that inhibit HIV-1 entry |
| Q27664086 | Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance |
| Q42321693 | Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry |
| Q52545389 | Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41. |
| Q39579319 | Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100 |
| Q41077802 | Direct interaction between the envelope and matrix proteins of HIV-1 |
| Q35853659 | Domains of the human immunodeficiency virus type 1 matrix and gp41 cytoplasmic tail required for envelope incorporation into virions. |
| Q37703084 | Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution |
| Q35182219 | Early steps of the conformational change of influenza virus hemagglutinin to a fusion active state: stability and energetics of the hemagglutinin |
| Q33676508 | Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail |
| Q39549670 | Effect of mutations in the second extracellular loop of CXCR4 on its utilization by human and feline immunodeficiency viruses. |
| Q45068181 | Enhancement of immunogenicity of an HIV Env DNA vaccine by mutation of the Tyr-based endocytosis motif in the cytoplasmic domain |
| Q34364045 | Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus |
| Q40056665 | Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions |
| Q39505913 | Expression of the extracellular domain of the human immunodeficiency virus type 1 envelope protein and its fusion with beta-galactosidase in Saccharomyces cerevisiae |
| Q33653971 | FIV Gag: virus assembly and host-cell interactions |
| Q34648092 | Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes |
| Q33802126 | Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail |
| Q35826780 | HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores |
| Q44807433 | HIV-1 Nef enhances both membrane expression and virion incorporation of Env products. A model for the Nef-dependent increase of HIV-1 infectivity |
| Q35113720 | HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation |
| Q37384536 | HIV-1 envelope gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes. |
| Q36040759 | HIV-1, reactive oxygen species, and vascular complications |
| Q35542610 | HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor |
| Q37179996 | Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India |
| Q45463275 | Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding |
| Q35889256 | Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences |
| Q36857103 | Human immunodeficiency virus type 1 assembly, release, and maturation. |
| Q33615123 | Identification and frequency of CCR5Δ32/Δ32 HIV-resistant cord blood units from Houston area hospitals. |
| Q36558933 | In silico Analysis of HIV-1 Env-gp120 Reveals Structural Bases for Viral Adaptation in Growth-Restrictive Cells |
| Q39881634 | Influence of membrane anchoring and cytoplasmic domains on the fusogenic activity of vesicular stomatitis virus glycoprotein G |
| Q28379257 | Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism |
| Q45762776 | Inhibition of influenza virus fusion by polyanionic proteins |
| Q42526189 | Initial characterization of viral sequences from a SHIV-inoculated pig-tailed macaque that developed AIDS. |
| Q38524164 | Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides. |
| Q43979274 | Kinetics of interaction of HIV fusion protein (gp41) with lipid membranes studied by real-time AFM imaging. |
| Q33559031 | Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity |
| Q40701425 | Long-term culture of HIV-1-infected cells with the transcription inhibitor K-37. |
| Q28143090 | Maturation of HIV envelope glycoprotein precursors by cellular endoproteases |
| Q41646890 | Membrane interactions of the synthetic N-terminal peptide of HIV-1 gp41 and its structural analogs |
| Q36424527 | Modulation of human immunodeficiency virus type 1 infectivity through incorporation of tetraspanin proteins |
| Q41450212 | Molecular characterization of HIV-1 genome in fission yeast Schizosaccharomyces pombe |
| Q37316122 | Molecular dynamics studies of the transmembrane domain of gp41 from HIV-1. |
| Q39648706 | Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. |
| Q40625213 | Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation |
| Q34333514 | Mutation of the dominant endocytosis motif in human immunodeficiency virus type 1 gp41 can complement matrix mutations without increasing Env incorporation |
| Q34070049 | Mutation-directed chemical cross-linking of human immunodeficiency virus type 1 gp41 oligomers. |
| Q36307738 | New insights into HIV assembly and trafficking |
| Q27665224 | Novel Fold and Carbohydrate Specificity of the Potent Anti-HIV Cyanobacterial Lectin from Oscillatoria agardhii |
| Q33802789 | Novel peptides based on HIV-1 gp120 sequence with homology to chemokines inhibit HIV infection in cell culture |
| Q27312753 | Nucleocapsid promotes localization of HIV-1 gag to uropods that participate in virological synapses between T cells |
| Q33642818 | Opposing effects of human immunodeficiency virus type 1 matrix mutations support a myristyl switch model of gag membrane targeting. |
| Q35189635 | Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection |
| Q35566715 | Palmitoylation of the HIV-1 envelope glycoprotein is critical for viral infectivity |
| Q35922555 | Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. |
| Q33315022 | Photoinduced reactivity of the HIV-1 envelope glycoprotein with a membrane-embedded probe reveals insertion of portions of the HIV-1 Gp41 cytoplasmic tail into the viral membrane |
| Q35873035 | Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry |
| Q40957198 | Processing and routage of HIV glycoproteins by furin to the cell surface |
| Q37950254 | Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. |
| Q39700279 | Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus |
| Q42209615 | RRE-dependent HIV-1 Env RNA effects on Gag protein expression, assembly and release |
| Q51455637 | Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics. |
| Q34741962 | Rational site-directed mutations of the LLP-1 and LLP-2 lentivirus lytic peptide domains in the intracytoplasmic tail of human immunodeficiency virus type 1 gp41 indicate common functions in cell-cell fusion but distinct roles in virion envelope inc |
| Q27642457 | Recurring conformation of the human immunodeficiency virus type 1 gp120 V3 loop |
| Q36090433 | Retroviral env glycoprotein trafficking and incorporation into virions |
| Q36973720 | Role of the HIV gp120 conserved domain 1 in processing and viral entry |
| Q54946721 | Role of the HIV-1 envelope transmembrane domain in intracellular sorting. |
| Q38920578 | Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity |
| Q32061666 | SIRE-1, a copia/Ty1-like retroelement from soybean, encodes a retroviral envelope-like protein |
| Q35893615 | Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loop |
| Q36871226 | Selectively infective phages (SIP). |
| Q28343901 | Sensitivity to a nonpeptidic compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region |
| Q35927570 | Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors |
| Q27764577 | Solution structure of cyanovirin-N, a potent HIV-inactivating protein |
| Q27671641 | Structural Basis of the Anti-HIV Activity of the Cyanobacterial Oscillatoria Agardhii Agglutinin |
| Q27641682 | Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion |
| Q42044906 | Structural characterization of the feline-immunodeficiency-virus envelope glycoprotein 36 ectodomain for the development of new antivirals |
| Q37683010 | Surface stability and immunogenicity of the human immunodeficiency virus envelope glycoprotein: role of the cytoplasmic domain |
| Q35616634 | Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41. |
| Q42638352 | TR1.3 viral pathogenesis and syncytium formation are linked to Env-Gag cooperation |
| Q35024116 | Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy |
| Q40387378 | The C34 Peptide Fusion Inhibitor Binds to the Six-Helix Bundle Core Domain of HIV-1 gp41 by Displacement of the C-Terminal Helical Repeat Region |
| Q27670815 | The Conformation and Orientation of a 27-Residue CCR5 Peptide in a Ternary Complex with HIV-1 gp120 and a CD4-Mimic Peptide |
| Q34412839 | The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry |
| Q36393161 | The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160 |
| Q47736276 | The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation. |
| Q37152680 | The long cytoplasmic tail of gp41 is required in a cell type-dependent manner for HIV-1 envelope glycoprotein incorporation into virions |
| Q34366384 | The membrane-spanning domain of gp41 plays a critical role in intracellular trafficking of the HIV envelope protein |
| Q38219405 | The roles of lipids and nucleic acids in HIV-1 assembly |
| Q24533287 | Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41 |
| Q33840847 | Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsorptive endocytosis |
| Q36535498 | Up-regulation of a cellular protein at the translational level by a retrovirus |
| Q52020246 | Use of human CD4 transgenic mice for studying immunogenicity of HIV-1 envelope protein gp120. |
| Q58591002 | Variable infectivity and conserved engagement in cell-to-cell viral transfer by HIV-1 Env from Clade B transmitted founder clones |
| Q41624661 | Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production |
Search more.